Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 2/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.36 |
| ▸ | ITGAL | P20701 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 4/20 | 0.34 |
| ▸ | HTR1A | P08908 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4641320 | 0.90 | ITGB2 (0.33) | ITGB2ICAM1ITGALMAPTSCN9A | |
| SCHEMBL14091801 | 0.87 | HTR1A (0.34) | ITGB2ICAM1ITGALHTR1ASLC6A4 | |
| SCHEMBL4962098 | 0.85 | ITGB2 (0.49) | ITGB2ICAM1ITGALMAPTTACR1 | |
| SCHEMBL4962092 | 0.85 | ITGB2 (0.49) | ITGB2ICAM1ITGALMAPTTACR1 | |
| SCHEMBL4802320 | 0.80 | ITGB2 (0.44) | ITGB2ICAM1ITGALMAPTTACR1 | |
| SCHEMBL14091790 | 0.80 | HTR1A (0.42) | ITGB2ICAM1ITGALHTR1ASLC6A4 | |
| SCHEMBL14091799 | 0.80 | HTR1A (0.36) | ITGB2ICAM1ITGALHTR1ASLC6A4 | |
| SCHEMBL14091791 | 0.78 | ITGB2 (0.45) | ITGB2ICAM1ITGALMAPTTACR1 | |
| SCHEMBL14091793 | 0.77 | GPR84 (0.33) | ITGB2ICAM1ITGALHTR1ASLC6A4 | |
| SCHEMBL14091846 | 0.77 | ITGB2 (0.44) | ITGB2ICAM1ITGALMAPTHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-08-28 | — | — | US | disclosed |
| EP-1956016-A1 | Bicyclic acyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008071455-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | FSHR, GNRHR, TPH1 | ITGB2 4184/4885ICAM1 4069/4885ITGAL 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.